Table IV.
LMFS and factors associated with LMFS
| Subgroup | Characteristic | LMFS* |
Univariable Cox regression† |
||||
|---|---|---|---|---|---|---|---|
| 5-y (%) | 10-y (%) | Log rank P value | LM/death | Crude HR | 95% CI | ||
| Overall | Age at surgery (per y) | - | - | NA | 37 of 153 | 1.03 | 1.01 – 1.06 |
| Sex | 87 | 77 | .491 | 18 of 66 | 1 | Ref cat | |
| Male | |||||||
| Female | 94 | 77 | 19 of 87 | 0.80 | 0.42–1.52 | ||
| pNET functionality | |||||||
| Insulinoma | 98 | 87 | .002 | 15 of 92 | 1 | Ref cat | |
| NF-pNET | 81 | 63 | 22 of 61 | 2.72 | 1.41–5.28 | ||
| Size continuous (per mm) | - | - | NA | 37 of 153 | 1.02 | 1.01 – 1.03 | |
| pNET 2 cm | |||||||
| <2 cm | 95 | 87 | .003 | 9 of 60 | 1 | Ref cat | |
| ≥2 cm | 88 | 70 | 28 of 93 | 2.97 | 1.36 – 6.48 | ||
| WHO grade | |||||||
| G1 | 93 | 80 | .002 | 21 of 109 | 1 | Ref cat | |
| G2/G3 | 83 | 42 | 16 of 44 | 2.20 | 1.02–4.76 | ||
| Lymph node status | |||||||
| No metastases | 91 | 81 | .144 | 12 of 60 | 1 | Ref cat | |
| None resected | 90 | 76 | 16 of 69 | 1.35 | 0.61–2.99 | ||
| Metastases | 86 | 51 | 9 of 24 | 2.77 | 1.12–6.85 | ||
| Y from diagnosis until surgery | - | - | NA | 37 of 153 | 1.12 | 1.01–1.24 | |
| NF-pNET | Age at surgery (per y) | - | - | NA | 22 of 61 | 1.04 | 0.995–1.08 |
| Sex | |||||||
| Male | 80 | 68 | .752 | 12 of 34 | 1 | Ref cat | |
| Female | 84 | 58 | 10 of 27 | 1.15 | 0.85–1.51 | ||
| Size continuous (per mm) | - | - | NA | 22 of 61 | 1.02 | 1.01–1.04 | |
| pNET 2 cm | |||||||
| <2 cm | 86 | 86 | .058 | 6 of 22 | 1 | Ref cat | |
| ≥2 cm | 80 | 50 | 16 of 39 | 2.37 | 0.89–6.34 | ||
| WHO grade | |||||||
| G1 | 86 | 73 | .046 | 14 of 47 | 1 | Ref cat | |
| G2/G3 | 74 | 24 | 8 of 14 | 2.99 | 1.19–7.54 | ||
| Lymph node status | |||||||
| No metastases | 77 | 77 | .360 | 5 of 14 | 1 | Ref cat | |
| None resected | 83 | 70 | 8 of 29 | 0.63 | 0.21–1.96 | ||
| Metastases | 82 | 44 | 9 of 18 | 1.28 | 0.42–3.94 | ||
| Y from diagnosis until surgery | - | - | NA | 22 of 61 | 1.01 | 0.88–1.16 | |
| Insulinoma | Age at surgery (per y) | - | - | NA | 15 of 92 | 1.02 | 0.99–1.06 |
| Sex | |||||||
| Male | 97 | 90 | .784 | 6 of 32 | 1 | Ref cat | |
| Female | 98 | 85 | 9 of 60 | 0.83 | 0.60–1.18 | ||
| Size continuous (per mm) | - | - | NA | 15 of 92 | 1.01 | 0.998–1.03 | |
| pNET 2 cm | |||||||
| <2 cm | 100 | 86 | .068 | 3 of 40 | 1 | Ref cat | |
| ≥2 cm | 95 | 87 | 12 of 52 | 3.43 | 0.98–12.01 | ||
| WHO grade | |||||||
| G1 | 100 | 90 | .003 | 7 of 62 | 1 | Ref cat | |
| G2/G3 | 91 | 68 | 8 of 30 | 2.60 | 0.92–7.29 | ||
| Lymph node status | 97 | 83 | .385 | 7 of 46 | 1 | Ref cat | |
| No metastases | |||||||
| None resected | 97 | 82 | 8 of 40 | 1.91 | 0.66–5.54 | ||
| Metastases | 100 | - | 0 of 6 | NA | NA | ||
| Y from diagnosis until surgery | - | - | NA | 15 of 92 | 1.25 | 1.05–1.49 | |
cat, category; NA, not applicable; Ref, reference.
*
Estimated survival percentages are based on the patients with complete data.
†
Data presented after multiple imputation.